| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ZHONG JI LONGEVITY SCIENCE GROUP Aktie jetzt für 0€ handeln | |||||
| Mo | ZHONG JI LS (00767): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF CIRCULAR OF ANNUAL GENERAL MEETING 2025 | - | HKEx | ||
| Mo | ZHONG JI LS (00767): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF CIRCULAR AND PROXY FORM OF ANNUAL GENERAL ... | - | HKEx | ||
| Mo | ZHONG JI LS (00767): NOTICE OF THE ANNUAL GENERAL MEETING | 1 | HKEx | ||
| Mo | ZHONG JI LS (00767): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| Mo | ZHONG JI LS (00767): PROPOSAL ON (1) RE-ELECTION OF RETIRING DIRECTORS, (2) RE-APPOINTMENT OF AUDITOR, (3) GENERAL MANDATES TO ISSUE SHARES AND TO REPURCHASE ... | - | HKEx | ||
| 30.04. | ZHONG JI LS (00767): FURTHER DELAY IN DESPATCH OF CIRCULAR MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN ... | - | HKEx | ||
| 27.04. | ZHONG JI LS (00767): NOTIFICATION LETTER TO NON-REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025 | 2 | HKEx | ||
| 27.04. | ZHONG JI LS (00767): NOTIFICATION LETTER TO REGISTERED SHAREHOLDERS AND REPLY FORM - NOTICE OF PUBLICATION OF ANNUAL REPORT 2025 | 2 | HKEx | ||
| 27.04. | ZHONG JI LS (00767): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx | ||
| 27.04. | ZHONG JI LS (00767): ANNUAL REPORT 2025 | 2 | HKEx | ||
| 13.04. | ZHONG JI LS (00767): VOLUNTARY ANNOUNCEMENT FORMATION OF A JOINT VENTURE | - | HKEx | ||
| 08.04. | ZHONG JI LS (00767): FURTHER DELAY IN DESPATCH OF CIRCULAR MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN ... | - | HKEx | ||
| 02.04. | ZHONG JI LS (00767): MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN INTEGRATED CELL LABORATORY LIMITED ... | 1 | HKEx | ||
| 26.03. | ZHONG JI LS (00767): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025 | 1 | HKEx | ||
| 16.03. | ZHONG JI LS (00767): DATE OF BOARD MEETING | 1 | HKEx | ||
| 09.03. | ZHONG JI LS (00767): FURTHER DELAY IN DESPATCH OF CIRCULAR MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN ... | 3 | HKEx | ||
| 10.02. | ZHONG JI LS (00767): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION | - | HKEx | ||
| 10.02. | ZHONG JI LS (00767): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND MEMBER OF THE BOARD COMMITTEES; AND COMPLIANCE WITH RULE 3.10(2) AND 3.21 OF ... | - | HKEx | ||
| 09.02. | ZHONG JI LS (00767): FURTHER DELAY IN DESPATCH OF CIRCULAR MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN ... | 3 | HKEx | ||
| 16.01. | ZHONG JI LS (00767): FURTHER DELAY IN DESPATCH OF CIRCULAR MAJOR AND CONNECTED TRANSACTION IN RELATION TO ACQUISITION OF 25% ISSUED SHARE CAPITAL OF ASIAN ... | - | HKEx |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 35,120 | -1,60 % | Bayer Aktie: Neue Rechtsklagen überlagern die Fortschritte | Frische Rechtsschlagzeilen aus den USA belasten die Bayer Aktie erneut. Zwei neue Fälle sorgen für Unruhe: Die Anfechtung des Roundup-Vergleichs wirft Fragen zum wichtigsten Entlastungsmeilenstein auf... ► Artikel lesen | |
| MERCK KGAA | 137,70 | +0,18 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
08.06.2026 / 16:57 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 65,28 | 0,00 % | BRIGHT MINDS BIOSCIENCES INC. - 6-K, Report of foreign issuer | ||
| ETON PHARMACEUTICALS | 29,950 | 0,00 % | Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO (miltefosine) | IMPAVIDO is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leishmaniasis caused by specific Leishmania speciesLeishmaniasis is a rare but potentially life-threatening... ► Artikel lesen | |
| NOVO NORDISK | 35,825 | +0,36 % | Börsenrotation ohne KI! Jetzt 100 % mit MustGrow, Bayer und Novo Nordisk, Achtung bei K+S | Erstellt und veröffentlicht im Auftrag von MustGrow Biologics Corp. Perspektivenwechsel bleibt das Gebot der Stunde. Denn gestern tagte die EZB zur aktuellen Lage bei Inflation und Zinsniveau. Mit einer... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 12,760 | -0,16 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| GSK | 21,370 | -3,30 % | DEUTSCHE BANK RESEARCH stuft GSK auf 'Hold' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für GSK mit einem Kursziel von 1900 Pence auf "Hold" belassen. Emmanuel Papadakis bezeichnete in seinem am Dienstag vorliegenden... ► Artikel lesen | |
| ZEALAND PHARMA | 36,840 | +9,32 % | Zealand Pharma-Aktie -25%: Ist jetzt der richtige Kaufzeitpunkt? | Es ist ein rabenschwarzer Tag für die Aktionäre von Zealand Pharma. Der Kurs des dänischen Biotech-Untenrehmens kollabiert zum Wochenbeginn um -25% und fällt damit fast auf ein neues 2-Jahrestief. Was... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 3,910 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| ELI LILLY | 1.004,40 | +0,82 % | ELI LILLY ist zuletzt auf ein Allzeithoch gestiegen | Der zentrale Auslöser war die neue Erstattungsvereinbarung mit CVS Caremark. Der Pharmacy-Benefit-Manager nimmt die GLP-1-Pille Foundayo ab 1. Juni und die Abnehm-Injektion Zepbound ab 1. Oktober in... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 11,400 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| MILESTONE PHARMACEUTICALS | 1,230 | 0,00 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update | CARDAMYST (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 11,550 | 0,00 % | Atrium Therapeutics Reports First Quarter 2026 Financial Results | SAN DIEGO, May 14, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics" or the "Company"), a biopharmaceutical company... ► Artikel lesen | |
| SEAPORT THERAPEUTICS | 16,200 | 0,00 % | Stifel reiterates Buy on Seaport Therapeutics stock, $30 target | ||
| LB PHARMACEUTICALS | 29,360 | -0,14 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update | Initiated two late-stage clinical trials of LB-102: the pivotal Phase 3 NOVA-2 trial in schizophrenia and the Phase 2 ILLUMINATE-1 trial in bipolar depression Published results from the Phase 2 NOVA-1... ► Artikel lesen |